Advances in the development of vaccines for dengue fever

References

• Ranjit S, Kissoon N. Dengue hemorrhagic fever and shock syndromes. Pedia.tr Crit Care Med. 2011;12(1):90–100.
   Web of Science ®Google Scholar
• Rico-Hesse R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology. 1990;174(2):479–493.
   Web of Science ®Google Scholar
• Gubler DJ. Dengue and dengue hemorrhagic fever. Clinical Microbiol Rev. 1998;11(3):480–496.
   PubMed Web of Science ®Google Scholar
• Rush B. An account of the bilious remitting fever, as it appeared in Philadelphia in the summer and autumn of the year 1780. In: Medical Inquiries and Observations. Philadelphia: Prichard and Hall; 1789:104–117.
   Google Scholar
• Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1(1):30–50.
   PubMedGoogle Scholar
• Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science. 1945;101(2634):640–642.
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5(7):518–528.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421–467.
   PubMed Web of Science ®Google Scholar
• Halstead SB. WHO fights dengue haemorrhagic fever. WHO Chron. 1982;36(2):65–67.
   Google Scholar
• Halstead SB, O’Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977;265(5596):739–741.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Chow JS, Marchette NJ. Immunological enhancement of dengue virus replication. Nat New Biol. 1973;243(122):24–26.
   Google Scholar
• Sriprom M, Pongsumpun P, Yoksan S, Gonzalez JP, Tang IM. Dengue haemorrhagic fever in Thailand, 1998–2003: primary or secondary infection. Dengue Bull. 2003;27:39–45.
   Google Scholar
• Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2–9.
   PubMed Web of Science ®Google Scholar
• Fried JR, Gibbons RV, Kalayanarooj S, et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis. 2010;4(3):e617.
   Web of Science ®Google Scholar
• Murrell S, Wu SC, Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv. 2011;29(2):239–247.
   PubMed Web of Science ®Google Scholar
• Kurane I, Innis BL, Nimmannitya S, et al. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest. 1991;88(5):1473–1480.
   Web of Science ®Google Scholar
• Rico-Hesse R, Harrison LM, Salas RA, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology. 1997;230(2):244–251.
   PubMed Web of Science ®Google Scholar
• Zhang C, Mammen MP Jr, Chinnawirotpisan P, et al. Structure and age of genetic diversity of dengue virus type 2 in Thailand. J Gen Virol. 2006;87(Pt 4):873–883.
   Google Scholar
• Wisseman CL Jr. Global medicine: a new dimension. Bull Sch Med Univ Md. 1963;48:1–4.
   Google Scholar
• Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1988;239(4839):476–481.
   PubMed Web of Science ®Google Scholar
• Bancroft WH, Scott RM, Eckels KH, et al. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. JInfect Dis. 1984;149(6):1005–1010.
   Web of Science ®Google Scholar
• Brandt WE. From the World Health Organization. Develop ment of dengue and Japanese encephalitis vaccines. J Infect Dis. 1990;162(3):577–583.
   Web of Science ®Google Scholar
• Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med. 2006;203(2):413–424.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis. 2008;198(4):500–507.
   PubMed Web of Science ®Google Scholar
• Vasilakis N, Cardosa J, Hanley KA, Holmes EC, Weaver SC. Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health. Nat Rev Microbiol. 2011;9(7):532–541.
   PubMed Web of Science ®Google Scholar
• Raheel U, Faheem M, Riaz MN, et al. Dengue fever in the Indian Subcontinent: an overview. J Infect Dev Ctries. 2011;5(4):239–247.
   PubMed Web of Science ®Google Scholar
• Kanakaratne N, Wahala WM, Messer WB, et al. Severe dengue epidem ics in Sri Lanka, 2003–2006. Emerg Infect Dis. 2009;15(2):192–199.
   Web of Science ®Google Scholar
• World Health Organization. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Hemorrhagic Fever. Revised and expanded edition. 2011. Available from: http://www.searo.who.int/en/ Section10/Section332/Section554.htm. Accessed February 22, 2012.
   Google Scholar
• World Health Organization. Dengue in Africa: emergence of DENV-3, Cote d’Ivoire, 2008. Wkly EpidemiolRec. 2009;84(11–12):85–88.
   Google Scholar
• San Martin JL, Brathwaite O, Zambrano B, et al. The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am JTrop MedHyg. 2010;82(1):128–135.
   PubMed Web of Science ®Google Scholar
• Khan NA, Azhar EI, El-Fiky S, et al. Clinical profile and outcome of hospitalized patients during first outbreak of dengue in Makkah, Saudi Arabia. Acta Trop. 2008;105(1):39–44.
   PubMed Web of Science ®Google Scholar
• Ravanini P, Huhtamo E, Hasu E, et al. Imported dengue virus serotype 3, Yemen to Italy, 2010. Emerg Infect Dis. 2011;17(5):929–931.
   Web of Science ®Google Scholar
• Amarasinghe A, Letson GW. Dengue in the Middle East: a neglected, emerging disease of importance. Trans R Soc Trop Med Hyg. 2012;106(1):1–2.
   Web of Science ®Google Scholar
• World Health Organization. Dengue and Severe Dengue. Fact sheet no 117. 2012. Available from: http://www.who.int/mediacentre/ factsheets/fs117/en/. Accessed February 22, 2012.
   Google Scholar
• Halstead SB. Dengue. Lancet. 2007;370(9599):1644–1652.
   Web of Science ®Google Scholar
• Kittigul L, Pitakarnjanakul P, Sujirarat D, Siripanichgon K. The differ ences of clinical manifestations and laboratory findings in children and adults with dengue virus infection. J Clin Virol. 2007;39(2):76–81.
   Web of Science ®Google Scholar
• Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clinical Microbiol Rev. 2009;22(4):564–581.
   PubMed Web of Science ®Google Scholar
• Hombach J. Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev Panam Salud Publica. 2007;21(4):254–260.
   PubMed Web of Science ®Google Scholar
• Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis. 2009;9(11):678–687.
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Defang G, Burgess T, Porter K. Advances in dengue vaccine development. Human Vaccin. 2009;5(8):520–528.
   PubMed Web of Science ®Google Scholar
• Danko JR, Beckett CG, Porter KR. Development of dengue DNA vaccines. Vaccine. 2011;29(42):7261–7266.
   PubMed Web of Science ®Google Scholar
• Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical devel opment of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29(42):7229–7241.
   PubMed Web of Science ®Google Scholar
• Coller BA, Clements DE. Dengue vaccines: progress and challenges. Curr Opin Immunol. 2011;23(3):391–398.
   PubMed Web of Science ®Google Scholar
• Gubler DJ. Emerging vector-borne flavivirus diseases: are vaccines the solution? Expert Rev Vaccines. 2011;10(5):563–565.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS. Next-generation dengue vaccines: novel strategies currently under development. Viruses. 2011;3(10):1800–1814.
   Web of Science ®Google Scholar
• Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine. 2011;29(42):7276–7284.
   PubMed Web of Science ®Google Scholar
• Edelman R. Unique challenges faced by the clinical evaluation of dengue vaccines. Expert Rev Vaccines. 2011;10(2):133–136.
   PubMed Web of Science ®Google Scholar
• Thomas SJ. The necessity and quandaries of dengue vaccine development. J Infect Dis. 2011;203(3):299–303.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis. 2011;24(5):442–450.
   PubMed Web of Science ®Google Scholar
• Bray M, Lai CJ. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci U S A. 1991;88(22):10342–10346.
   PubMed Web of Science ®Google Scholar
• Pletnev AG, Bray M, Huggins J, Lai CJ. Construction and characteriza tion of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc Natl Acad Sci U S A. 1992;89(21):10532–10536.
   PubMed Web of Science ®Google Scholar
• Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/ Japanese encephalitis chimeric viruses: construction and biological properties. J Virol. 1999;73(4):3095–3101.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Weltzin R, Chambers TJ, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000;74(12):5477–5485.
   PubMed Web of Science ®Google Scholar
• Lai CJ, Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res. 2003;61:469–509.
   PubMedGoogle Scholar
• Mantel N, Girerd Y, Geny C, et al. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine. 2011;29(38):6629–6635.
   PubMed Web of Science ®Google Scholar
• Monath TP, Kanesa-Thasan N, Guirakhoo F, et al. Recombination and flavivirus vaccines: a commentary. Vaccine. 2005;23(23):2956–2958.
   Web of Science ®Google Scholar
• Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Human Vaccin. 2006;2(2):60–67.
   PubMed Web of Science ®Google Scholar
• Morrison AC, Minnick SL, Rocha C, et al. Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission. PLoS Negl Trop Dis. 2010;4(5):e670.
   Web of Science ®Google Scholar
• Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg. 2011;85(4):724–731.
   PubMed Web of Science ®Google Scholar
• Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. Epub October 29, 2010.
   Google Scholar
• Capeding RZ, Luna IA, Bomasang E, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011;29(22):3863–3872.
   PubMed Web of Science ®Google Scholar
• Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3’ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol. 1996;70(6):3930–3937.
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly atten uated and immunogenic in monkeys. J Virol. 2003;77(2):1653–1657.
   PubMed Web of Science ®Google Scholar
• Blaney JE Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis. 2004;4:39.
   PubMed Web of Science ®Google Scholar
• Troyer JM, Hanley KA, Whitehead SS, et al. A live attenuated recom binant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg. 2001;65(5):414–419.
   Web of Science ®Google Scholar
• Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3’-untranslated region. Am J Trop Med Hyg. 2001;65(5):405–413.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS, McArthur J, et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immuno genic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005;191(5):710–718.
   PubMed Web of Science ®Google Scholar
• Durbin AP, McArthur J, Marron JA, et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Human Vaccin. 2006;2(4):167–173.
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Wang D, Ewing D, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol. 2008;82(14):6927–6934.
   PubMed Web of Science ®Google Scholar
• Beckett CG, Tjaden J, Burgess T, et al. Evaluation of a prototype dengue -1 DNA vaccine in a phase 1 clinical trial. Vaccine. 2011;29(5):960–968.
   PubMed Web of Science ®Google Scholar
• Kochel TJ, Raviprakash K, Hayes CG, et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine. 2000;18(27):3166–3173.
   Web of Science ®Google Scholar
• Raviprakash K, Kochel TJ, Ewing D, et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine. 2000;18(22):2426–2434.
   PubMed Web of Science ®Google Scholar
• Porter KR, Ewing D, Chen L, et al. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine. 2012;30(2):336–341.
   PubMed Web of Science ®Google Scholar
• Lima DM, de Paula SO, Franca RF, et al. A DNA vaccine candi date encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection. Vaccine. 2011;29(4):831–838.
   Web of Science ®Google Scholar
• Costa SM, Yorio AP, Goncalves AJ, et al. Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines. PloS One. 2011;6(10):e25685.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Fan D, Gao N, et al. Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection. Vaccine. 2011;29(4):763–771.
   Web of Science ®Google Scholar
• Putnak R, Barvir DA, Burrous JM, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immu- nogenicity and protection in mice and rhesus monkeys. J Infect Dis. 1996;174(6):1176–1184.
   PubMed Web of Science ®Google Scholar
• Putnak R, Cassidy K, Conforti N, et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg. 1996;55(5):504–510.
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Putnak JR, Lee SH, et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine. 2001;19(31):4557–4565.
   PubMed Web of Science ®Google Scholar
• Eckels KH, Putnak R. Formalin-inactivated whole virus and recombi nant subunit flavivirus vaccines. Adv Virus Res. 2003;61:395–418.
   PubMedGoogle Scholar
• Tauber E, Dewasthaly S. Japanese encephalitis vaccines - needs, flaws and achievements. Biological Chem. 2008;389(5):547–550.
   Web of Science ®Google Scholar
• Kaltenbock A, Dubischar-Kastner K, Eder G, et al. Safety and immuno- genicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine. 2009;27(33):4483–4489.
   PubMed Web of Science ®Google Scholar
• Van Gessel Y, Klade CS, Putnak R, et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO) induced neutralizing antibody titers. Vaccine. 2011;29(35):5925–5931.
   PubMed Web of Science ®Google Scholar
• Putnak R, Porter K, Schmaljohn C. DNA vaccines for flaviviruses. Adv Virus Res. 2003;61:445–468.
   Google Scholar
• Simmons M, Burgess T, Lynch J, Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology. 2010;396(2):280–288.
   PubMed Web of Science ®Google Scholar
• Coller BA, Barrett AD, Thomas SJ. The development of Dengue vaccines. Introduction. Vaccine. 2011;29(42):7219–7220.
   Google Scholar
• Clements DE, Coller BA, Lieberman MM, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and effi cacy studies in mice and monkeys. Vaccine. 2010;28(15):2705–2715.
   PubMed Web of Science ®Google Scholar
• Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. 2011;29(42):7251–7260.
   PubMed Web of Science ®Google Scholar
• Brewoo JN, Kinney RM, Powell TD, et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine. 2012;30(8):1513–1520.
   PubMed Web of Science ®Google Scholar
• Simmons M, Porter KR, Escamilla J, et al. Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies. Am J Trop Med Hyg. 1998;58(2):144–151.
   Web of Science ®Google Scholar
• Simmons M, Murphy GS, Kochel T, Raviprakash K, Hayes CG. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am J Trop Med Hyg. 2001;65(5):420–426.
   PubMed Web of Science ®Google Scholar
• Simmons M, Murphy GS, Hayes CG. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg. 2001;65(2):159–161.
   PubMed Web of Science ®Google Scholar
• Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, Schlesinger JJ. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine. 2010;28(51):8085–8094.
   Web of Science ®Google Scholar
• Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392(1):103–113.
   PubMed Web of Science ®Google Scholar
• Brandler S, Ruffie C, Najburg V et al. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine. 2010;28(41):6730–6739.
   PubMed Web of Science ®Google Scholar
• Maves RC, Ore RM, Porter KR, Kochel T J. Immunogenicity and protec - tive efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine. 2011;29(15):2691–2696.
   Web of Science ®Google Scholar
• Smith KM, Nanda K, Spears CJ, et al. Structural mutants of dengue virus 2 transmembrane domains exhibit host-range phenotype. Virol J. 2011;8:289.
   Web of Science ®Google Scholar
• Block TM, Lu X, Mehta A, Park J, Blumberg BS, Dwek R. Role of glycan processing in hepatitis B virus envelope protein trafficking. Adv Exp Med Biol. 1998;435:207–216.
   Web of Science ®Google Scholar
• Block TM, Lu X, Platt FM, et al. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl AcadSci USA. March 15, 1994;91(6):2235–2239.
   Web of Science ®Google Scholar
• Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov. 2002;1(1):65–75.
   PubMed Web of Science ®Google Scholar
• Gu B, Mason P, Wang L, et al. Antiviral profiles of novel iminocyclitol com pounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir Chem Chemother. 2007;18(1):49–59.
   PubMedGoogle Scholar
• Miller JL, de Wet BJ, Martinez-Pomares L, et al. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 2008;4(2):e17.
   PubMed Web of Science ®Google Scholar
• Menendez A, Calarese DA, Stanfield RL, et al. A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J. 2008;22(5):1380–1392.
   PubMed Web of Science ®Google Scholar
• Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct. 1998;27:249–284.
   PubMedGoogle Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426(6963):186–189.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Turner RB, Gwaltney JM, et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother. 2003;47(12):3907–3916.
   PubMed Web of Science ®Google Scholar
• Phoon CW, Ng PY, Ting AE, Yeo SL, Sim MM. Biological evalua tion of hepatitis C virus helicase inhibitors. Bioorg Med Chem Lett. 2001;11(13):1647–1650.
   Web of Science ®Google Scholar
• Belon CA, Frick DN. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol. 2009;4(3):277–293.
   Web of Science ®Google Scholar
• Gozdek A, Zhukov I, Polkowska A, et al. NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system. AntimicrobAgents Chemother. 2008;52(2):393–401.
   Web of Science ®Google Scholar
• Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A. Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI). Biochem Pharmacol. 2008;76(1):28–38.
   Web of Science ®Google Scholar
• Maga G, Gemma S, Fattorusso C, et al. Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. Biochemistry. 2005;44(28):9637–9644.
   Web of Science ®Google Scholar
• Kandil S, Biondaro S, Vlachakis D, et al. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorg Med Chem Lett. 2009;19(11):2935–2937.
   Web of Science ®Google Scholar
• Noble CG, Chen YL, Dong H, et al. Strategies for development of Dengue virus inhibitors. Antiviral Res. 2010;85(3):450–462.
   PubMed Web of Science ®Google Scholar
• Migliaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside ana logs that inhibit hepatitis C virus replication in vitro. J Biol Chem. 2003;278(49):49164–49170.
   Web of Science ®Google Scholar
• Yin Z, Chen YL, Schul W, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A. 2009;106(48):20435–20439.
   PubMed Web of Science ®Google Scholar
• Chen YL, Yin Z, Lakshminarayana SB, et al. Inhibition of dengue virus by an ester prodrug of an adenosine analog. Antimicrob Agents Chemother. 2010;54(8):3255–3261.
   PubMed Web of Science ®Google Scholar
• Costin JM, Jenwitheesuk E, Lok SM, et al. Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLoS Negl Trop Dis. 2010;4(6):e721.
   PubMed Web of Science ®Google Scholar
• Nicholson CO, Costin JM, Rowe DK, et al. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro. Antiviral Res. 2011;89(1):71–74.
   PubMed Web of Science ®Google Scholar
• Yang JM, Chen YF, Tu YY, Yen KR, Yang YL. Combinatorial com putational approaches to identify tetracycline derivatives as flavivirus inhibitors. PloS One. 2007;2(5):e428.
   PubMed Web of Science ®Google Scholar
• Kaptein SJ, De Burghgraeve T, Froeyen M, et al. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus repli cation in vitro. Antimicrob Agents Chemother. 2010;54(12):5269–5280.
   PubMed Web of Science ®Google Scholar
• Le Calvez H, Yu M, Fang F. Biochemical prevention and treatment of viral infections - a new paradigm in medicine for infectious diseases. Virology J. 2004;1:12.
   Web of Science ®Google Scholar
• Tuschl T. Expanding small RNA interference. Nat Biotechnol. 2002;20(5):446–448.
   PubMed Web of Science ®Google Scholar
• Alhoot MA, Wang SM, Sekaran SD. Inhibition of dengue virus entry and multiplication into monocytes using RNA interference. PLoS Negl Trop Dis. 2011;5(11):e1410.
   PubMed Web of Science ®Google Scholar
• Chang J, Schul W, Butters TD, et al. Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 2011;89(1):26–34.
   Web of Science ®Google Scholar
• Zandi K, Teoh BT, Sam SS, Wong PF, Mustafa MR, Abubakar S. Antiviral activity of four types of bioflavonoid against dengue virus type-2. Virology J. 2011;8:560.
   PubMed Web of Science ®Google Scholar
• Talarico LB, Pujol CA, Zibetti RG, et al. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res. 2005;66(2–3):103–110.
   PubMed Web of Science ®Google Scholar
• Laille M, Gerald F, Debitus C. In vitro antiviral activity on dengue virus of marine natural products. Cell Mol Life Sci. 1998;54(2):167–170.
   Web of Science ®Google Scholar
• Parida MM, Upadhyay C, Pandya G, Jana AM. Inhibitory potential of neem (Azadirachta indica Juss) leaves on dengue virus type-2 replica tion. JEthnopharmacol. 2002;79(2):273–278.
   PubMed Web of Science ®Google Scholar
• Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman NA. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg Med Chem Lett. 2006;16(12):3337–3340.
   PubMed Web of Science ®Google Scholar
• Muhamad M, Kee LY, Rahman NA, Yusof R. Antiviral actions of flavanoid-derived compounds on dengue virus type-2. Int J Biol Sci. 2010;6(3):294–302.
   Web of Science ®Google Scholar
• Tang LI, Ling AP, Koh RY, Chye SM, Voon KG. Screening of anti-dengue activity in methanolic extracts of medicinal plants. BMC Complement Altern Med. 2012;12:3.
   PubMed Web of Science ®Google Scholar
• Pauwels F, Mostmans W, Quirynen LM, et al. Binding-site identifica tion and genotypic profiling of hepatitis C virus polymerase inhibitors. J Virol. 2007;81(13):6909–6919.
   Web of Science ®Google Scholar
• Beaumier CM, Jaiswal S, West KY, Friberg H, Mathew A, Rothman AL. Differential in vivo clearance and response to second ary heterologous infections by H2(b)-restricted dengue virus-specific CD8+ T cells. Viral Immunol. 2010;23(5):477–485.
   Web of Science ®Google Scholar
• Guzman MG, Vazquez S. The complexity of antibody-dependent enhance ment of dengue virus infection. Viruses. 2010;2(12):2649–2662.
   PubMed Web of Science ®Google Scholar
• Gunther VJ, Putnak R, Eckels KH, et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine. 2011;29(22):3895–3904.
   PubMed Web of Science ®Google Scholar
• Anderson KB, Gibbons RV, Edelman R, et al. Interference and facili tation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis. 2011;204(3):442–450.
   PubMed Web of Science ®Google Scholar
• Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. Forecasting dengue vaccine demand in disease endemic and non endemic countries. Human Vaccin. 2010;6(9):745–753.
   PubMed Web of Science ®Google Scholar
• Carrasco LR, Lee LK, Lee VJ, et al. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Negl Trop Dis. 2011;5(12):e1426.
   PubMed Web of Science ®Google Scholar
• Lee LK, Thein TL, Kurukularatne C, Gan V, Lye DC, Leo YS. Dengue knowledge, attitudes, and practices among primary care physicians in Singapore. Ann Acad Med Singapore. 2011;40(12):533–536.
   PubMed Web of Science ®Google Scholar
• Beatty ME, Beutels P, Meltzer MI, et al. Health economics of dengue: a systematic literature review and expert panel’s assessment. Am J Trop Med Hyg. 2011;84(3):473–488.
   PubMed Web of Science ®Google Scholar
• Gubler DJ, Suharyono W, Tan R, Abidin M, Sie A. Viraemia in patients with naturally acquired dengue infection. Bull World Health Organ. 1981;59(4):623–630.
   Web of Science ®Google Scholar
• Houng HS, Chung-Ming Chen R, Vaughn DW, Kanesa-thasan N. Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1–4 using conserved and serotype-specific 3′ noncoding sequences. J Virol Methods. 2001;95(1–2):19–32.
   PubMed Web of Science ®Google Scholar
• Houng HH, Hritz D, Kanesa-thasan N. Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3′-noncoding sequence. J Virol Methods. 2000;86(1):1–11.
   Web of Science ®Google Scholar
• Dussart P, Labeau B, Lagathu G, et al. Evaluation of an enzyme immunoassay for detection of dengue virus NS1 antigen in human serum. Clinical Vaccine Immunol. 2006;13(11):1185–1189.
   PubMedGoogle Scholar